Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction

about

Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction

Item

http://www.wikidata.org/entity/Q41129527

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cardiac Myosin Activation with ...... with Reduced Ejection Fraction

@en

type

Item

label

Cardiac Myosin Activation with ...... with Reduced Ejection Fraction

@en

prefLabel

Cardiac Myosin Activation with ...... with Reduced Ejection Fraction

@en

P1476

Cardiac Myosin Activation with ...... with Reduced Ejection Fraction

@en

P2093

Kassandra S Thomson

http://www.w3.org/2001/XMLSchema#string

Michael Regnier

http://www.w3.org/2001/XMLSchema#string

Sam L Teichman

http://www.w3.org/2001/XMLSchema#string

P2860

Inotropes.

Heart failure gene therapy: the path to clinical practice.

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Transgenic overexpression of ribonucleotide reductase improves cardiac performance.

Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts.

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

The structural basis for the allosteric regulation of ribonucleotide reductase.

Calcium regulation of tension redevelopment kinetics with 2-deoxy-ATP or low [ATP] in rabbit skeletal muscle.

ATP analogs and muscle contraction: mechanics and kinetics of nucleoside triphosphate binding and hydrolysis.

The effect of ATP analogs on posthydrolytic and force development steps in skinned skeletal muscle fibers.

P304

447-464

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/164_2016_31

http://www.w3.org/2001/XMLSchema#string

P478

243

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27590227

http://www.w3.org/2001/XMLSchema#string

P921

gene therapy

P932

5527752

http://www.w3.org/2001/XMLSchema#string